Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.

Abstract

PURPOSE:

Bevacizumab is the only therapeutic target approved for patients with persistent, recurrent or advanced cervical cancer from a phase III study that combined with chemotherapy; it proves a significant increase in overall survival. To retrospectively assess the efficacy and safety of bevacizumab as the first-line treatment in patients from usual clinical practice with recurrent/persistent or advanced cervical cancer.

PATIENTS AND METHODS:

Treatment consisted of cisplatin 50 mg/m2 or carboplatin AUC 5 plus paclitaxel 175 mg/m2 for 6-8 cycles and bevacizumab 15 mg/kg every 3 weeks up to progression or unacceptable toxicity. The endpoints were progression-free survival (PFS), overall survival (OS), response rates (RR) and toxicity.

RESULTS:

Twenty-seven patients were included from January 2014 to June 2017, with a median follow-up 10, 1 months. Eleven percent had recurrent/persistent disease and 89% had metastatic disease at diagnosis. The prior exposition to platinum was 70%. The median PFS and OS were 9, 6 and 21, 5 months, respectively. There was an increase of fistula formation (22%). All of them had pelvic and peritoneal disease at the beginning of treatment and previous treatment with chemoradiotherapy; non-incidence differences were found according to the type of platinum agent used. There were two treatment-related deaths, one from intestinal perforation and another from severe sepsis.

CONCLUSION:

Finally, although our study does have certain limitations, we believe that it can provide useful information and encouraging evidence that the routine use of bevacizumab as part of first-line treatment of patients with advanced cervical cancer may be associated with outcomes comparable with those obtained in GOG240 study.

• Authors: A Godoy-Ortiz, Y Plata, J Alcaide, A Galeote, B Pajares, E Saez, E Alba, A Sánchez-Muñoz
• Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (Clin Transl Oncol) Vol. 20 Issue 7 Pg. 922-927 (Jul 2018) ISSN: 1699-3055 [Electronic] Italy
• PMID: 29222647 (Publication Type: Journal Article)

Chemical References

• Bevacizumab
• Carboplatin
• Paclitaxel
• Cisplatin

Topics

• Adenocarcinoma (drug therapy, pathology)
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab (administration & dosage)
• Carboplatin (administration & dosage)
• Carcinoma, Squamous Cell (drug therapy, pathology)
• Cisplatin (administration & dosage)
• Clinical Trials, Phase III as Topic
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy, pathology)
• Paclitaxel (administration & dosage)
• Prognosis
• Retrospective Studies
• Survival Rate
• Uterine Cervical Neoplasms (drug therapy, pathology)